Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Johnson & Johnson (NYSE: JNJ ) on Monday reported topline results from its Phase 3 study evaluating Caplyta (lumateperone) for adults experiencing manic episodes linked to bipolar I disorder. The trial successfully met its primary endpoint, demonstrating a statistically significant and rapid reduction in manic symptoms
ETF investors have an unusual second-order trade due to exorbitant AI spending. Chicago Fed President Austan Goolsbee warned Monday that a surge in AI investment is pushing aggregate demand beyond what the U.S. economy can comfortably absorb. If AI spending keeps running into constraints around electricity, constructio